(Q34413734)

English

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

0 references

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens (English)

1 reference

Europe PubMed Central

2 August 2017

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Caubet JF

1

1 reference

Europe PubMed Central

2 August 2017

Tosteson TD

2

1 reference

Europe PubMed Central

2 August 2017

Dong EW

3

1 reference

Europe PubMed Central

2 August 2017

Naylon EM

4

1 reference

Europe PubMed Central

2 August 2017

Whiting GW

5

1 reference

Europe PubMed Central

2 August 2017

Ernstoff MS

6

1 reference

Europe PubMed Central

2 August 2017

Ross SD

7

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

1 January 1997

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

49

1 reference

Europe PubMed Central

2 August 2017

71-78

1 reference

Europe PubMed Central

2 August 2017

1

1 reference

Europe PubMed Central

2 August 2017

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A general parametric approach to the meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination treatment in M1 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Total androgen blockade: the United States experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparability of prostate trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bias in treatment assignment in controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900325-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(96)00325-1

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34413734&oldid=1549771686"